Volixibat
As of the edition of 20 October 2026, Volixibat is a small molecule: in active development; acts on SLC10A2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 5, 2 stopped early
- Disease areas
- Digestive system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Volixibat.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC10A2 | Ileal sodium/bile acid cotransporter | Q12908 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 4 | 0 | 2 | 2 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Mirum Pharmaceuticals | Lead sponsor of trials | 2015 to now |